Business
Phio Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update
Lead program, PH-762, is on track to enter first-in-human clinical study in Q1 2022 Presented data at the ESMO Congress 2021 showing Dual-Targeting INTASYL
About this update from Phio Pharmaceuticals Corp.
[{"type":"text","content":"Lead program, PH-762, is on track to enter first-in-human clinical study in Q1 2022\n Presented data at the ESMO Congress 2021 showing Dual-Targeting INTASYL PH-3861 induced a durable and specific systemic anti-tumor immune response following local administration\n\n\nMARLBOROUGH, Mass., Nov. 10, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today reported its financial results for the quarter ended September 30, 2021 and provided a business update.\nLogo - https://mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg \n\"Our development programs continue to generate positive in vivo data showing how INTASYL technology can be utilized in various applications to treat cancer. These data have generated broad interest in our programs as we prepare to enter the clinic with the initiation of two trials expected in the next couple of quarters,\" said Dr. Gerrit Dispersyn, President and CEO of Phio. \"We expect to initiate our first-in-human clinical study of our lead program, PH-762, in the first quarter of 2022, which will be followed by the first study with PH-762-empowered tumor infiltrating lymphocyte therapy to start in Q2. In addition, we've generated a lot of exciting in vivo data in support of the development of our PH-894 compound, showing it provides enhanced immunotherapeutic activity by reprograming T cells and other cells in the TME, and supporting our plans to file for a clinical trial application with the FDA in the second half of 2022.\"\nQuarter in Review and Recent Corporate Updates\nPresented positive data from several in vivo preclinical studies demonstrating the flexibility and application of INTASYL in the field of immuno-oncology at leading scientific conferences held during the third quarter of 2021: Announced new data showing that local treatment in vivo with INTASYL has the potential to cure locally treated and distal untreated tumors and generate systemic tumor immunity that is both durable and tumor specific, further highlighting the technology's potential in direct therapeutic applications. Data from this study, presented at the European Society of Medical Oncology (ESMO) Congress 2021, showed a complete response in u...